Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

  • Cancer Cell. 2026 Jun 8;44(6):1179-1200.e14. doi: 10.1016/j.ccell.2026.03.015.
Triet Minh Bui  1 Ernesto Rojas Jimenez  1 Zheqi Li  1 Pierre Foidart  1 Julieann Puleo  1 Pengze Yan  1 Aashna Jhaveri  2 Lin Yang  2 Jun Nishida  1 Marco Seehawer  1 Xinran Cai  1 Kimberly Ann Parker  1 Xiaodi Qin  3 Oyku Ece Sumer  4 Xiao-Yun Huang  4 Ashka Patel  5 Deborah Dillon  6 Charles H McDonnell 3rd  7 Ron Rowberry  7 Shinedeep Jhajj  7 Catherine Baker  7 Daniel D Brown  8 Siri H Strand  9 Jeffrey R Marks  10 Graham A Colditz  11 So Yeon Park  12 Adrian V Lee  13 Michael Angelo  9 Priscilla F McAuliffe  14 Kristie Bobolis  7 Robert West  9 Glenn Dranoff  4 E Shelley Hwang  10 Simona Cristea  2 Kornelia Polyak  15
Affiliations
  • 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
  • 3. Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27705, USA.
  • 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • 6. Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • 7. Sutter Institute for Medical Research, Roseville, CA 95661, USA.
  • 8. Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
  • 9. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • 10. Department of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
  • 11. Department of Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA.
  • 12. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.
  • 13. Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA; UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • 14. UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • 15. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].
Abstract

Immune escape during the ductal carcinoma in situ (DCIS)-to-invasive breast Cancer (IBC) transition shapes tumor evolution. Through transcriptomic mapping of the immune landscapes of normal breast, DCIS, and IBC from large patient cohorts, we identified T and myeloid cells as the primary distinguishing features between DCIS and IBC. We discovered cycling regulatory T cells (cycTreg) as an orchestrator of immunosuppression in IBC. cycTreg frequency predicts cytotoxic CD8+, TCR diversity, disease-specific survival in IBC, and recurrence in DCIS. In a rat model of breast Cancer, we demonstrated that cycTreg act as precursors to mature Treg and are inducible by tumor-localized type 2 dendritic cells. Profiling of tumors subjected to αOX40 and αPD-L1 therapies revealed an IL-33-mediated fibroblast-cycTreg signaling loop, the disruption of which enhances intratumoral antigen-experienced CD8+ effectors and systemic immunosurveillance. Our study defines cycTreg as critical inducers of immune escape and promising immuno-oncology targets in breast Cancer.

Keywords
dendritic cells; ductal carcinoma in situ; immune escape; immuno-oncology; progenitor T cells; regulatory T cells; single-cell transcriptomic atlas.
Products
Inhibitors & Agonists
Other Products